Xujia Zhang
张旭家
Xujia Zhang is a biotech entrepreneur and the founder, chairman, and CEO of Zhitai Bio (质肽生物), a peptide drug company . He holds a PhD from Peking University and previously served as a researcher at the Institute of Biophysics, Chinese Academy of Sciences . In 2007 he joined Novo Nordisk as VP of R&D, where he built the *E. coli* recombinant protein technology platform and led more than 30 programs . He has spent over three decades in biopharma and research . In 2024, Zhitai Bio licensed its GLP-1 semaglutide injection to Tonghua Dongbao , and the company closed a Series C round exceeding RMB 500 million in early 2026 .
AI-generated — may contain errors, please verify.
Coverage
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
BlueRun Ventures Continues to Double Down as QLT Biotherapeutics Closes Over RMB 500 Million Series C Round | BlueRun Family
Accelerate core clinical pipeline development
BlueRun Ventures in Conversation with QUA Biotech, AllinkBio, and Zenitar: Breaking Out of the Red Sea — The "Value" Evolution of China's Innovative Drugs
The Leap from "Imitation and Followership" to "Original Innovation"
Zhitai Bio's GLP-1 Product Semaglutide Injection Licensed to Tonghua Dongbao | BlueRun Ventures Headlines
It has the potential to become one of the first semaglutide biosimilars to be approved and commercially launched in China.
The Trillion-Yuan Blueprint for Peptide Drugs: From Diabetes Medication to Weight-Loss Wonder | BlueRun Ventures Biotech Forum Recap
From Pharmaceuticals to Consumer Goods: A Wave of Value Creation
BlueRun Ventures | BlueRun Ventures Continues to Double Down, Zhitai Bio Closes Nearly RMB 200 Million Series B+ Round
Focused on developing recombinant protein therapeutics using an *E. coli*-based technology platform.
